Pipeline
Focused on the Future
Our robust pipeline is strategically diversified across several therapeutic areas in ophthalmology that represent attractive market opportunities and continued growth potential. Our product candidates are engineered to address specific therapeutic needs across ocular surface, anterior segment and posterior segment diseases, including the leading causes of blindness. With an aging population, there is a clear growing need for these types of innovative ocular therapies that may enhance the overall patient and physician experience.
| Program | Therapeutic Focus | Preclinical | Early/Mid Clinical Stage (Phase 1 – Phase 2) | Pivotal Clinical Trial Stage (Phase 3) | FDA Approval | Next Milestones | ||
|---|---|---|---|---|---|---|---|---|
|
Program
|
Therapeautic Process
Post surgical ocular inflammation and pain
Ocular itching associated with allergic conjunctivitis |
Preclinical
|
Early/Mid Clinical Stage (Phase 1 – Phase 2)
|
Pivotal Clinical Trial Stage (Phase 3)
|
FDA Approval
|
| Program | Therapeutic Focus | Preclinical | Early/Mid Clinical Stage (Phase 1 – Phase 2) | Pivotal Clinical Trial Stage (Phase 3) | FDA Approval | Next Milestones | ||
|---|---|---|---|---|---|---|---|---|
|
Program
|
Therapeautic Process
Wet AMD*
|
Preclinical
|
Early/Mid Clinical Stage (Phase 1 – Phase 2)
|
Pivotal Clinical Trial Stage (Phase 3)
|
FDA Approval
|
|||
|
Program
|
Therapeautic Process
Diabetic Retinopathy
|
Preclinical
|
Early/Mid Clinical Stage (Phase 1 – Phase 2)
|
Pivotal Clinical Trial Stage (Phase 3)
|
FDA Approval
|
|||
|
Program
|
Therapeautic Process
Glaucoma and ocular hypertension
|
Preclinical
|
Early/Mid Clinical Stage (Phase 1 – Phase 2)
|
Pivotal Clinical Trial Stage (Phase 3)
|
FDA Approval
|
|||
|
Program
|
Therapeautic Process
Episodic dry eye disease
|
Preclinical
|
Early/Mid Clinical Stage (Phase 1 – Phase 2)
|
Pivotal Clinical Trial Stage (Phase 3)
|
FDA Approval
|
|||
|
Program
|
Therapeautic Process
Dry eye disease
|
Preclinical
|
Early/Mid Clinical Stage (Phase 1 – Phase 2)
|
Pivotal Clinical Trial Stage (Phase 3)
|
FDA Approval
|
| Program | Therapeutic Focus | Preclinical | Early/Mid Clinical Stage (Phase 1 – Phase 2) | Pivotal Clinical Trial Stage (Phase 3) | FDA Approval | Next Milestones | ||
|---|---|---|---|---|---|---|---|---|
|
Program
|
Therapeautic Process
Intermediate and late dry AMD*
|
Preclinical
|
Early/Mid Clinical Stage (Phase 1 – Phase 2)
|
Pivotal Clinical Trial Stage (Phase 3)
|
FDA Approval
|
|||
|
Program
|
Therapeautic Process
Inherited retinal degenerations and protein biofactory indications
|
Preclinical
|
Early/Mid Clinical Stage (Phase 1 – Phase 2)
|
Pivotal Clinical Trial Stage (Phase 3)
|
FDA Approval
|
* Age-related Macular Degeneration (AMD)
† Subject to FDA discussions of future clinical trial requirements and obtaining necessary financing; ‡ Subject to confirmatory Phase 1 readout
Caution: All product candidates are investigational and currently undergoing clinical evaluation. This chart is not intended to convey any conclusion of safety of efficacy, and there is no guarantee that any product candidate will successfully complete development or gain FDA approval.
